DK0859613T3 - Anvendelse af flupirtin til forebyggelse og behandling af sygdomme, som er forbundet med beskadigelse af det hæmopoietiske cellesystem - Google Patents

Anvendelse af flupirtin til forebyggelse og behandling af sygdomme, som er forbundet med beskadigelse af det hæmopoietiske cellesystem

Info

Publication number
DK0859613T3
DK0859613T3 DK96945822T DK96945822T DK0859613T3 DK 0859613 T3 DK0859613 T3 DK 0859613T3 DK 96945822 T DK96945822 T DK 96945822T DK 96945822 T DK96945822 T DK 96945822T DK 0859613 T3 DK0859613 T3 DK 0859613T3
Authority
DK
Denmark
Prior art keywords
flupirtine
treatment
cell system
diseases associated
prevention
Prior art date
Application number
DK96945822T
Other languages
English (en)
Inventor
Gabriela Pergande
Werner E G Mueller
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Application granted granted Critical
Publication of DK0859613T3 publication Critical patent/DK0859613T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK96945822T 1995-11-07 1996-10-23 Anvendelse af flupirtin til forebyggelse og behandling af sygdomme, som er forbundet med beskadigelse af det hæmopoietiske cellesystem DK0859613T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19541405A DE19541405A1 (de) 1995-11-07 1995-11-07 Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen

Publications (1)

Publication Number Publication Date
DK0859613T3 true DK0859613T3 (da) 2006-06-06

Family

ID=7776799

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96945822T DK0859613T3 (da) 1995-11-07 1996-10-23 Anvendelse af flupirtin til forebyggelse og behandling af sygdomme, som er forbundet med beskadigelse af det hæmopoietiske cellesystem

Country Status (27)

Country Link
US (2) US6034111A (da)
EP (1) EP0859613B1 (da)
JP (1) JPH11514652A (da)
KR (1) KR100512673B1 (da)
CN (1) CN1116037C (da)
AT (1) ATE316789T1 (da)
AU (1) AU711207B2 (da)
BG (1) BG63149B1 (da)
BR (1) BR9611588A (da)
CA (1) CA2189705C (da)
CZ (1) CZ298115B6 (da)
DE (2) DE19541405A1 (da)
DK (1) DK0859613T3 (da)
ES (1) ES2257755T3 (da)
HK (1) HK1016508A1 (da)
HU (1) HU225742B1 (da)
MX (1) MX9803610A (da)
NO (1) NO315074B1 (da)
NZ (1) NZ330414A (da)
PL (1) PL186537B1 (da)
PT (1) PT859613E (da)
RU (1) RU2200555C2 (da)
SK (1) SK284601B6 (da)
TW (1) TW393317B (da)
UA (1) UA51682C2 (da)
WO (1) WO1997017072A2 (da)
ZA (1) ZA968783B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102009023162B4 (de) * 2009-05-29 2011-07-07 Corden PharmaChem GmbH, 68305 Verfahren zur Herstellung von Flupirtin
JP5650739B2 (ja) * 2009-08-07 2015-01-07 スウエイジロク・カンパニー 低真空下での低温浸炭
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
WO2013127539A2 (de) * 2012-03-02 2013-09-06 Meda Pharma Gmbh & Co. Kg Pharmazeutische formulierungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN172468B (da) * 1990-07-14 1993-08-14 Asta Medica Ag
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin

Also Published As

Publication number Publication date
NO315074B1 (no) 2003-07-07
CN1116037C (zh) 2003-07-30
NO981898L (no) 1998-04-27
WO1997017072A2 (de) 1997-05-15
CZ298115B6 (cs) 2007-06-27
US6034111A (en) 2000-03-07
BR9611588A (pt) 1999-04-06
HU225742B1 (en) 2007-07-30
BG63149B1 (bg) 2001-05-31
DE19541405A1 (de) 1997-05-15
EP0859613B1 (de) 2006-02-01
US6034112A (en) 2000-03-07
PT859613E (pt) 2006-06-30
CA2189705A1 (en) 1997-05-08
JPH11514652A (ja) 1999-12-14
HUP9901659A2 (hu) 1999-09-28
NZ330414A (en) 1999-10-28
DE59611327D1 (de) 2006-04-13
ZA968783B (en) 1997-05-27
BG102404A (en) 1998-12-30
EP0859613A2 (de) 1998-08-26
SK284601B6 (sk) 2005-07-01
KR100512673B1 (ko) 2005-12-09
PL186537B1 (pl) 2004-01-30
ES2257755T3 (es) 2006-08-01
WO1997017072A3 (de) 1997-07-24
TW393317B (en) 2000-06-11
CZ128398A3 (cs) 1998-09-16
PL326629A1 (en) 1998-10-12
SK58698A3 (en) 1998-09-09
RU2200555C2 (ru) 2003-03-20
HK1016508A1 (en) 1999-11-05
AU1716597A (en) 1997-05-29
KR19990067366A (ko) 1999-08-16
ATE316789T1 (de) 2006-02-15
NO981898D0 (no) 1998-04-27
HUP9901659A3 (en) 2001-04-28
AU711207B2 (en) 1999-10-07
CN1201391A (zh) 1998-12-09
UA51682C2 (uk) 2002-12-16
MX9803610A (es) 1998-09-30
CA2189705C (en) 2005-08-09

Similar Documents

Publication Publication Date Title
ES2134764T3 (es) Inhibidores de hiv proteasa.
NO922949L (no) Forbindelser og fremgangsmaater for inhibering av hiv- og beslektede virus
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
DK0859613T3 (da) Anvendelse af flupirtin til forebyggelse og behandling af sygdomme, som er forbundet med beskadigelse af det hæmopoietiske cellesystem
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
NO962000L (no) Prolegemidler av en inhibitor av HIV-protease
NO20000446D0 (no) Anvendelse av fysiologisk akseptable vanadiumforbindelser, salter og komplekser
NO960775L (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
MX9308025A (es) Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
ZA991029B (en) Composition and methods for treatment of hiv infections.
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
AP9801286A0 (en) Therapeutic compounds.
EE03514B1 (et) Ühendite kombinatsioon HIV infektsiooni või AIDS-i raviks, selle kasutamine ja farmatseutiline kompositsioon
NZ512850A (en) Treatment of papillomavirus infections
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
FR2787028B1 (fr) Utilisation du riluzole dans le traitement des traumatismes acoustiques
NO965591L (no) Kombinasjonsbehandling av HIV-infeksjon
AU2396900A (en) Treatment and prevention of hiv and other viral infections
DK0910405T3 (da) Vaccine, som indeholder caprint arthritis-encephalitis-virus, og anvendelse til immunbeskyttelse imod HIV-1-infektion
SE9602262D0 (sv) New use of derivatives of cystine
DK0545991T3 (da) Peptider, der blokerer infektioner med human immundefektvirus, og fremgangsmåder til anvendelse deraf
WO1988008707A3 (en) Rubradirin derivatives for treatment of hiv infection
AU2450900A (en) Therapeutic nucleoside compound